{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:03:58Z","timestamp":1784210638267,"version":"3.55.0"},"publisher-location":"Cham","reference-count":105,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031972966","type":"print"},{"value":"9783031972973","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-3-031-97297-3_16","type":"book-chapter","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T17:08:56Z","timestamp":1761325736000},"page":"193-216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Current Role of CAR-T Therapy in Haematological Care"],"prefix":"10.1007","author":[{"given":"Miroslava","family":"Jandov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"L\u00e1nsk\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"S\u00fdkorov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Gregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Rozs\u00edvalov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Bekov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana Woidigov\u00e1","family":"Duch\u00e1\u010dov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Radocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glyn N.","family":"Stacey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"M\u011b\u0159i\u010dka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"issue":"3","key":"16_CR1","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/jlb.64.3.275","volume":"64","author":"KD Elgert","year":"1998","unstructured":"Elgert KD, Alleva DG, Mullins DW. Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol. 1998;64(3):275\u201390.","journal-title":"J Leukoc Biol"},{"issue":"1","key":"16_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/25785826.2019.1698261","volume":"43","author":"M Ando","year":"2020","unstructured":"Ando M, Ito M, Srirat T, Kondo T, Yoshimura A. Memory T cell, exhaustion, and tumor immunity. Immunol Med. 2020;43(1):1\u20139.","journal-title":"Immunol Med"},{"issue":"2","key":"16_CR3","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.coi.2012.12.003","volume":"25","author":"J Crespo","year":"2013","unstructured":"Crespo J, Sun H, Welling TH, Tian Z, Zou W. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol. 2013;25(2):214\u201321.","journal-title":"Curr Opin Immunol"},{"issue":"Suppl 2","key":"16_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3747\/co.27.5285","volume":"27","author":"SD Saibil","year":"2020","unstructured":"Saibil SD, Ohashi PS. Targeting T cell activation in immuno-oncology. Curr Oncol. 2020;27(Suppl 2):98\u2013105.","journal-title":"Curr Oncol"},{"issue":"3","key":"16_CR5","first-page":"197","volume":"8","author":"A Gratwohl","year":"1991","unstructured":"Gratwohl A. Bone marrow transplantation activity in Europe 1990. European Group for Bone Marrow Transplantation (EBMT). Bone Marrow Transplant. 1991;8(3):197\u2013201.","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"16_CR6","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1473-3099(12)70187-1","volume":"12","author":"T Malag\u00f3n","year":"2012","unstructured":"Malag\u00f3n T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(10):781\u20139.","journal-title":"Lancet Infect Dis"},{"issue":"47","key":"16_CR7","doi-asserted-by":"publisher","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","volume":"22","author":"MR Smith","year":"2003","unstructured":"Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22(47):7359\u201368.","journal-title":"Oncogene"},{"key":"16_CR8","first-page":"3","volume":"166","author":"I Hellstr\u00f6m","year":"2001","unstructured":"Hellstr\u00f6m I, Hellstr\u00f6m KE, Senter PD. Development and activities of the BR96-doxorubicin immunoconjugate. Methods Mol Biol. 2001;166:3\u201316.","journal-title":"Methods Mol Biol"},{"issue":"2","key":"16_CR9","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1200\/JCO.1999.17.2.478","volume":"17","author":"AW Tolcher","year":"1999","unstructured":"Tolcher AW, Sugarman S, Gelmon KA, Cohen R, Saleh M, Isaacs C, et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol. 1999;17(2):478\u201384.","journal-title":"J Clin Oncol"},{"issue":"12","key":"16_CR10","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1038\/sj.bjc.6601367","volume":"89","author":"R Repp","year":"2003","unstructured":"Repp R, van Ojik HH, Valerius T, Groenewegen G, Wieland G, Oetzel C, et al. Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI \u00d7 anti-HER-2\/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer. Br J Cancer. 2003;89(12):2234\u201343.","journal-title":"Br J Cancer"},{"issue":"4","key":"16_CR11","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388\u201398.","journal-title":"Cancer Discov"},{"issue":"1","key":"16_CR12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-015-0205-6","volume":"8","author":"D Fan","year":"2015","unstructured":"Fan D, Li W, Yang Y, Zhang X, Zhang Q, Yan Y, et al. Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 \u00d7 anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells. J Hematol Oncol. 2015;8(1):108.","journal-title":"J Hematol Oncol"},{"key":"16_CR13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13045-015-0109-5","volume":"8","author":"D Fan","year":"2015","unstructured":"Fan D, Li Z, Zhang X, Yang Y, Yuan X, Zhang X, et al. AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells. J Hematol Oncol. 2015;8:18.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"16_CR14","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807\u201321.","journal-title":"Cell Mol Immunol"},{"issue":"15","key":"16_CR15","first-page":"3369","volume":"55","author":"P Hwu","year":"1995","unstructured":"Hwu P, Yang JC, Cowherd R, Treisman J, Shafer GE, Eshhar Z, et al. In vivo antitumor activity of T cells redirected with chimeric antibody\/T-cell receptor genes. Cancer Res. 1995;55(15):3369\u201373.","journal-title":"Cancer Res"},{"issue":"20 Pt 1","key":"16_CR16","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","volume":"12","author":"MH Kershaw","year":"2006","unstructured":"Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12(20 Pt 1):6106\u201315.","journal-title":"Clin Cancer Res"},{"issue":"24","key":"16_CR17","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 1989;86(24):10024\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"16_CR18","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nm827","volume":"9","author":"RJ Brentjens","year":"2003","unstructured":"Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. 2003;9(3):279\u201386.","journal-title":"Nat Med"},{"issue":"95","key":"16_CR19","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73.","journal-title":"Sci Transl Med"},{"issue":"5","key":"16_CR20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"key":"16_CR21","doi-asserted-by":"publisher","first-page":"1113882","DOI":"10.3389\/fimmu.2023.1113882","volume":"14","author":"A Daei Sorkhabi","year":"2023","unstructured":"Daei Sorkhabi A, Mohamed Khosroshahi L, Sarkesh A, Mardi A, Aghebati-Maleki A, Aghebati-Maleki L, et al. The current landscape of CAR T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies. Front Immunol. 2023;14:1113882.","journal-title":"Front Immunol"},{"issue":"10","key":"16_CR22","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","volume":"27","author":"S Cordoba","year":"2021","unstructured":"Cordoba S, Onuoha S, Thomas S, Pignataro DS, Hough R, Ghorashian S, et al. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. Nat Med. 2021;27(10):1797\u2013805.","journal-title":"Nat Med"},{"issue":"2","key":"16_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","volume":"18","author":"L Mikkilineni","year":"2021","unstructured":"Mikkilineni L, Kochenderfer JN. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol. 2021;18(2):71\u201384.","journal-title":"Nat Rev Clin Oncol"},{"issue":"17","key":"16_CR24","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1200\/JCO.19.03279","volume":"38","author":"NN Shah","year":"2020","unstructured":"Shah NN, Highfill SL, Shalabi H, Yates B, Jin J, Wolters PL, et al. CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial. J Clin Oncol. 2020;38(17):1938\u201350.","journal-title":"J Clin Oncol"},{"issue":"399","key":"16_CR25","doi-asserted-by":"publisher","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"DM O\u2019Rourke","year":"2017","unstructured":"O\u2019Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399):eaaa0984.","journal-title":"Sci Transl Med"},{"issue":"8","key":"16_CR26","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","volume":"3","author":"N Ahmed","year":"2017","unstructured":"Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, et al. HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol. 2017;3(8):1094\u2013101.","journal-title":"JAMA Oncol"},{"issue":"16","key":"16_CR27","first-page":"1586","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, JULIET Investigators. Tisagenlecleucel in diffuse large B-cell lymphoma. Reply. N Engl J Med. 2019;380(16):1586.","journal-title":"N Engl J Med"},{"issue":"26","key":"16_CR28","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"key":"16_CR29","doi-asserted-by":"publisher","first-page":"953","DOI":"10.12659\/MSM.890496","volume":"20","author":"YW Zang","year":"2014","unstructured":"Zang YW, Gu XD, Xiang JB, Chen ZY. Clinical application of adoptive T cell therapy in solid tumors. Med Sci Monit. 2014;20:953\u20139.","journal-title":"Med Sci Monit"},{"issue":"1","key":"16_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.12125","volume":"257","author":"M Chmielewski","year":"2014","unstructured":"Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev. 2014;257(1):83\u201390.","journal-title":"Immunol Rev"},{"issue":"1","key":"16_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","volume":"120","author":"N Tokarew","year":"2019","unstructured":"Tokarew N, Ogonek J, Endres S, von Bergwelt-Baildon M, Kobold S. Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer. 2019;120(1):26\u201337.","journal-title":"Br J Cancer"},{"issue":"8","key":"16_CR32","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1080\/14712598.2022.2086043","volume":"22","author":"F Furqan","year":"2022","unstructured":"Furqan F, Shah NN. Bispecific CAR T-cells for B-cell malignancies. Expert Opin Biol Ther. 2022;22(8):1005\u201315.","journal-title":"Expert Opin Biol Ther"},{"key":"16_CR33","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1146\/annurev-med-042921-024719","volume":"74","author":"F Furqan","year":"2023","unstructured":"Furqan F, Shah NN. Multispecific CAR T cells deprive lymphomas of escape via antigen loss. Annu Rev Med. 2023;74:279\u201391.","journal-title":"Annu Rev Med"},{"issue":"8","key":"16_CR34","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1182\/blood.2022016200","volume":"141","author":"MM Berrien-Elliott","year":"2023","unstructured":"Berrien-Elliott MM, Jacobs MT, Fehniger TA. Allogeneic natural killer cell therapy. Blood. 2023;141(8):856\u201368.","journal-title":"Blood"},{"key":"16_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.783305","volume":"12","author":"C Sloas","year":"2021","unstructured":"Sloas C, Gill S, Klichinsky M. Engineered CAR-macrophages as adoptive immunotherapies for solid tumors. Front Immunol. 2021;12:783305.","journal-title":"Front Immunol"},{"issue":"6","key":"16_CR36","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382(6):545\u201353.","journal-title":"N Engl J Med"},{"issue":"7","key":"16_CR37","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):640\u201354.","journal-title":"N Engl J Med"},{"issue":"14","key":"16_CR38","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.2022018730","volume":"141","author":"JS Abramson","year":"2023","unstructured":"Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023;141(14):1675\u201384.","journal-title":"Blood"},{"issue":"26","key":"16_CR39","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321\u201330.","journal-title":"Blood"},{"issue":"4","key":"16_CR40","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"16_CR41","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M, Stemmler HJ, Schl\u00f6\u00dfer HA, Schlaak M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"16_CR42","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"PJ Hayden","year":"2022","unstructured":"Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022;33(3):259\u201375.","journal-title":"Ann Oncol"},{"issue":"Suppl 4","key":"16_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000746","volume":"4","author":"L Y\u00e1\u00f1ez","year":"2020","unstructured":"Y\u00e1\u00f1ez L, Alarc\u00f3n A, S\u00e1nchez-Escamilla M, Perales MA. How I treat adverse effects of CAR-T cell therapy. ESMO Open. 2020;4(Suppl 4):e000746.","journal-title":"ESMO Open"},{"issue":"2","key":"16_CR44","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"NH Fowler","year":"2022","unstructured":"Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28(2):325\u201332.","journal-title":"Nat Med"},{"issue":"1","key":"16_CR45","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356.","journal-title":"N Engl J Med"},{"key":"16_CR46","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/mto.2016.15","volume":"3","author":"X Wang","year":"2016","unstructured":"Wang X, Rivi\u00e8re I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics. 2016;3:16015.","journal-title":"Mol Ther Oncolytics"},{"issue":"10299","key":"16_CR47","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491\u2013502.","journal-title":"Lancet"},{"issue":"10254","key":"16_CR48","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839\u201352.","journal-title":"Lancet"},{"issue":"8","key":"16_CR49","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"6","key":"16_CR50","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41(6):1265\u201374.","journal-title":"J Clin Oncol"},{"issue":"10297","key":"16_CR51","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324.","journal-title":"Lancet"},{"issue":"9","key":"16_CR52","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","volume":"121","author":"JC Riches","year":"2013","unstructured":"Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013;121(9):1612\u201321.","journal-title":"Blood"},{"key":"16_CR53","doi-asserted-by":"publisher","first-page":"204062072211430","DOI":"10.1177\/20406207221143025","volume":"13","author":"L Luo","year":"2022","unstructured":"Luo L, Zhou X, Zhou L, Liang Z, Yang J, Tu S, et al. Current state of CAR-T therapy for T-cell malignancies. Ther Adv Hematol. 2022;13:20406207221143025.","journal-title":"Ther Adv Hematol"},{"issue":"5","key":"16_CR54","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11912-023-01380-x","volume":"25","author":"G Guzman","year":"2023","unstructured":"Guzman G, Reed MR, Bielamowicz K, Koss B, Rodriguez A. CAR-T therapies in solid tumors: opportunities and challenges. Curr Oncol Rep. 2023;25(5):479\u201389.","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"16_CR55","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood.V96.3.785.015k10_785_793","volume":"96","author":"RT Mitsuyasu","year":"2000","unstructured":"Mitsuyasu RT, Anton PA, Deeks SG, Scadden DT, Connick E, Downs MT, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood. 2000;96(3):785\u201393.","journal-title":"Blood"},{"issue":"6","key":"16_CR56","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos D, Kr\u00f6nke G, V\u00f6lkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med. 2021;385(6):567\u20139.","journal-title":"N Engl J Med"},{"issue":"10","key":"16_CR57","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, M\u00fcller F, Mougiakakos D, B\u00f6ltz S, Wilhelm A, Aigner M, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28(10):2124\u201332.","journal-title":"Nat Med"},{"issue":"10379","key":"16_CR58","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","volume":"401","author":"F M\u00fcller","year":"2023","unstructured":"M\u00fcller F, Boeltz S, Knitza J, Aigner M, V\u00f6lkl S, Kharboutli S, et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet. 2023;401(10379):815\u20138.","journal-title":"Lancet"},{"key":"16_CR59","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.3389\/fimmu.2019.02711","volume":"10","author":"M Seif","year":"2019","unstructured":"Seif M, Einsele H, L\u00f6ffler J. CAR T cells beyond cancer: hope for immunomodulatory therapy of infectious diseases. Front Immunol. 2019;10:2711.","journal-title":"Front Immunol"},{"issue":"1","key":"16_CR60","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nbt0102-70","volume":"20","author":"J Maher","year":"2002","unstructured":"Maher J, Brentjens RJ, Gunset G, Rivi\u00e8re I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta\/CD28 receptor. Nat Biotechnol. 2002;20(1):70\u20135.","journal-title":"Nat Biotechnol"},{"issue":"5","key":"16_CR61","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.ymthe.2005.04.016","volume":"12","author":"MA Pul\u00e8","year":"2005","unstructured":"Pul\u00e8 MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005;12(5):933\u201341.","journal-title":"Mol Ther"},{"issue":"17","key":"16_CR62","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","volume":"119","author":"BG Till","year":"2012","unstructured":"Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. 2012;119(17):3940\u201350.","journal-title":"Blood"},{"issue":"1","key":"16_CR63","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jocn.2013.03.012","volume":"21","author":"BD Choi","year":"2014","unstructured":"Choi BD, Suryadevara CM, Gedeon PC, Herndon JE, Sanchez-Perez L, Bigner DD, et al. Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. J Clin Neurosci. 2014;21(1):189\u201390.","journal-title":"J Clin Neurosci"},{"issue":"17","key":"16_CR64","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","volume":"71","author":"M Chmielewski","year":"2011","unstructured":"Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 2011;71(17):5697\u2013706.","journal-title":"Cancer Res"},{"issue":"7","key":"16_CR65","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","volume":"5","author":"G Krenciute","year":"2017","unstructured":"Krenciute G, Prinzing BL, Yi Z, Wu MF, Liu H, Dotti G, et al. Transgenic expression of IL15 improves antiglioma activity of IL13R\u03b12-CAR T cells but results in antigen loss variants. Cancer Immunol Res. 2017;5(7):571\u201381.","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"16_CR66","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nm.4478","volume":"24","author":"Y Kagoya","year":"2018","unstructured":"Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang CH, Saso K, et al. A novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects. Nat Med. 2018;24(3):352\u20139.","journal-title":"Nat Med"},{"issue":"7","key":"16_CR67","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa2116596","volume":"386","author":"MR Bishop","year":"2022","unstructured":"Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med. 2022;386(7):629\u201339.","journal-title":"N Engl J Med"},{"issue":"1","key":"16_CR68","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91\u2013103.","journal-title":"Lancet Oncol"},{"issue":"14","key":"16_CR69","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331\u201342.","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"16_CR70","doi-asserted-by":"publisher","first-page":"TPS7566","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS7566","volume":"37","author":"I Flinn","year":"2019","unstructured":"Flinn I, Marris M, Wierda WG, Coutre S, Pagel JM, Byrd JC, et al. ZUMA-8: a phase 1\/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL). J Clin Oncol. 2019;37(15_suppl):TPS7566.","journal-title":"J Clin Oncol"},{"issue":"12","key":"16_CR71","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1182\/blood.2021011895","volume":"139","author":"T Siddiqi","year":"2022","unstructured":"Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, et al. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed\/refractory CLL or SLL. Blood. 2022;139(12):1794\u2013806.","journal-title":"Blood"},{"issue":"Supplement 1","key":"16_CR72","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1182\/blood-2022-170201","volume":"140","author":"S Naik","year":"2022","unstructured":"Naik S, Madden RM, Lipsitt A, Lockey T, Bran J, Rubnitz JE, et al. Safety and anti-leukemic activity of CD123-CAR T cells in pediatric patients with AML: preliminary results from a phase 1 trial. Blood. 2022;140(Supplement 1):4584\u20135.","journal-title":"Blood"},{"key":"16_CR73","volume-title":"EudraLex \u2013 Volume 4 \u2013 Good Manufacturing Practice (GMP) guidelines","author":"European Commission","year":"2017","unstructured":"European Commission. EudraLex \u2013 Volume 4 \u2013 Good Manufacturing Practice (GMP) guidelines. European Commission; 2017. Available from: https:\/\/ec.europa.eu\/health\/medicinal-products\/eudralex\/eudralex-volume-4_en."},{"key":"16_CR74","volume-title":"Reference product exclusivity for biological products filed under 351(a) of the PHS Act","author":"Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry","year":"2014","unstructured":"Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry. Reference product exclusivity for biological products filed under 351(a) of the PHS Act. Food and Drug Administration; 2014."},{"issue":"1","key":"16_CR75","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.eng.2018.12.003","volume":"5","author":"Y Li","year":"2019","unstructured":"Li Y, Huo Y, Yu L, Wang J. Quality control and nonclinical research on CAR-T cell products: general principles and key issues. Engineering. 2019;5(1):122\u201331.","journal-title":"Engineering"},{"issue":"5","key":"16_CR76","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","volume":"2","author":"M Abou-el-Enein","year":"2021","unstructured":"Abou-el-Enein M, Elsallab M, Feldman SA, Fesnak AD, Heslop HE, Marks P, et al. Scalable manufacturing of CAR T cells for cancer immunotherapy. Blood Cancer Discov. 2021;2(5):408\u201322.","journal-title":"Blood Cancer Discov"},{"key":"16_CR77","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","volume":"4","author":"BL Levine","year":"2017","unstructured":"Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 2017;4:92\u2013101.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"16_CR78","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-94353-0","volume-title":"The EBMT\/EHA CAR-T cell handbook","author":"N Kr\u04e7ger","year":"2022","unstructured":"Kr\u04e7ger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H, European Society for Blood and Marrow Transplantation, et al. The EBMT\/EHA CAR-T cell handbook. Cham: Springer; 2022. Available from: https:\/\/ezproxy.library.dal.ca\/login?url=https:\/\/doi.org\/10.1007\/978-3-030-94353-0."},{"issue":"3","key":"16_CR79","doi-asserted-by":"publisher","first-page":"123","DOI":"10.54680\/fr23310110112","volume":"44","author":"M Jandov\u00e1","year":"2023","unstructured":"Jandov\u00e1 M, Stacey GN, L\u00e1nsk\u00e1 M, Gregor J, Rozs\u00edvalov\u00e1 P, Bekov\u00e1 L, et al. Perspective: the role of cryopreservation techniques in manufacturing, transport, and storage of car-T therapy products. CryoLetters. 2023;44(3):123\u201333.","journal-title":"CryoLetters"},{"issue":"7","key":"16_CR80","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.ymthe.2019.05.015","volume":"27","author":"SR Panch","year":"2019","unstructured":"Panch SR, Srivastava SK, Elavia N, McManus A, Liu S, Jin P, et al. Effect of cryopreservation on autologous chimeric antigen receptor T cell characteristics. Mol Ther. 2019;27(7):1275\u201385.","journal-title":"Mol Ther"},{"key":"16_CR81","series-title":"Reference series in biomedical engineering","first-page":"1","volume-title":"Cell engineering and regeneration","author":"JP Acker","year":"2022","unstructured":"Acker JP, Bondarovych M, Brunotte R, Buriak IA, Fuller BJ, Glasmacher B, et al. Preservation and storage of cells for therapy: current applications and protocols. In: Gimble JM, Marolt Presen D, Oreffo ROC, Wolbank S, Redl H, editors. Cell engineering and regeneration, Reference series in biomedical engineering. Cham: Springer International Publishing; 2022. p. 1\u201369. Available from: https:\/\/link.springer.com\/10.1007\/978-3-319-37076-7_68-1."},{"key":"16_CR82","unstructured":"International Council for Commonality in Blood Banking Automation. ISBT 128 standard \u2013 applying ISBT 128 labels to collection products for further manufacture [Internet]. ISBT 128. 2021. Available from: https:\/\/www.isbt128.org\/_files\/ugd\/83d6e1_c73c1716101447f290fc1f6edba65744.pdf."},{"key":"16_CR83","unstructured":"European Directorate for the Quality of Medicines, Consell d\u2019Europa. Guide to the quality and safety of tissues and cells for human application [Internet]. 2022 [cited April 13, 2022]. Available from: https:\/\/freepub.edqm.eu\/publications\/AUTOPUB_17\/detail."},{"issue":"10","key":"16_CR84","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/s41409-023-02072-7","volume":"58","author":"K Nezvalova-Henriksen","year":"2023","unstructured":"Nezvalova-Henriksen K, Langebrake C, Bauters T, Moreno-Martinez ME, Ahnfelt E, Ekelund H, et al. Implementation and operational management of marketed chimeric antigen receptor T cell (CAR-T Cell) therapy-a guidance by the GoCART Coalition Pharmacist Working Group. Bone Marrow Transplant. 2023;58(10):1069\u201374.","journal-title":"Bone Marrow Transplant"},{"key":"16_CR85","unstructured":"Specialist Pharmacy Service. Accessing the CAR-T training passport for clinical pharmacists [Internet]. 2023. Available from: https:\/\/www.sps.nhs.uk\/articles\/accessing-the-car-t-training-passport-for-clinical-pharmacists\/."},{"issue":"2","key":"16_CR86","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3324\/haematol.2019.229781","volume":"105","author":"I Yakoub-Agha","year":"2020","unstructured":"Yakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica. 2020;105(2):297\u2013316.","journal-title":"Haematologica"},{"key":"16_CR87","unstructured":"Parliament of the Czech Republic. Act no. 78\/2004 Coll. The Act on the management of genetically modified organisms and genetic products. Collection of Laws, No. 78. 2004."},{"key":"16_CR88","unstructured":"European Commission. EU Coding Platform Reference Compendia for the Application of a single European Coding System for Tissues and Cells [Internet]. Available from: https:\/\/webgate.ec.europa.eu\/eucoding\/reports\/te\/index.xhtml."},{"issue":"3","key":"16_CR89","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.2217\/rme-2019-0145","volume":"15","author":"M Awan","year":"2020","unstructured":"Awan M, Buriak I, Fleck R, Fuller B, Goltsev A, Kerby J, et al. Dimethyl sulfoxide: a central player since the dawn of cryobiology, is efficacy balanced by toxicity? Regen Med. 2020;15(3):1463\u201391.","journal-title":"Regen Med"},{"issue":"4","key":"16_CR90","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1182\/blood.V70.4.974.974","volume":"70","author":"PJ Stiff","year":"1987","unstructured":"Stiff PJ, Koester AR, Weidner MK, Dvorak K, Fisher RI. Autologous bone marrow transplantation using unfractionated cells cryopreserved in dimethylsulfoxide and hydroxyethyl starch without controlled-rate freezing. Blood. 1987;70(4):974\u20138.","journal-title":"Blood"},{"key":"16_CR91","first-page":"372","volume":"42","author":"P M\u011b\u0159i\u010dka","year":"2021","unstructured":"M\u011b\u0159i\u010dka P, Gregor J, Jandov\u00e1 M, L\u00e1nsk\u00e1 M, Vokurkov\u00e1 D, F\u00e1torov\u00e1 I, et al. Cryopreservation of allogeneic haematopoetic progenitor cells (HPC) concentrates before transplantation \u2013 temporary or prospected solution. Cryo Letters. 2021;42:372.","journal-title":"Cryo Letters"},{"issue":"13","key":"16_CR92","doi-asserted-by":"publisher","DOI":"10.1172\/JCI152477","volume":"131","author":"M Hegde","year":"2021","unstructured":"Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, et al. Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape. J Clin Invest. 2021;131(13):e152477.","journal-title":"J Clin Invest"},{"issue":"6258","key":"16_CR93","doi-asserted-by":"publisher","first-page":"aab4077","DOI":"10.1126\/science.aab4077","volume":"350","author":"CY Wu","year":"2015","unstructured":"Wu CY, Roybal KT, Puchner EM, Onuffer J, Lim WA. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science. 2015;350(6258):aab4077.","journal-title":"Science"},{"key":"16_CR94","first-page":"1914","volume":"1","author":"LC Fleischer","year":"2017","unstructured":"Fleischer LC, Raikar SS, Moot R, Knight KA, Doering CB, Spencer TH. Engineering CD5-targeted chimeric antigen receptors and edited T cells for the treatment of T-cell leukemia. Blood. 2017;1:1914.","journal-title":"Blood"},{"issue":"9","key":"16_CR95","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","volume":"32","author":"ML Cooper","year":"2018","unstructured":"Cooper ML, Choi J, Staser K, Ritchey JK, Devenport JM, Eckardt K, et al. An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia. 2018;32(9):1970\u201383.","journal-title":"Leukemia"},{"issue":"2","key":"16_CR96","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000188","volume":"3","author":"S Charrot","year":"2019","unstructured":"Charrot S, Hallam S. CAR-T cells: future perspectives. HemaSphere. 2019;3(2):e188.","journal-title":"HemaSphere"},{"issue":"1","key":"16_CR97","doi-asserted-by":"publisher","first-page":"5225","DOI":"10.1038\/s41467-022-32866-0","volume":"13","author":"U Blache","year":"2022","unstructured":"Blache U, Popp G, D\u00fcnkel A, Koehl U, Fricke S. Potential solutions for manufacture of CAR T cells in cancer immunotherapy. Nat Commun. 2022;13(1):5225.","journal-title":"Nat Commun"},{"key":"16_CR98","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1201\/9780203647073.ch17","volume-title":"Life in the frozen state","author":"A Sputtek","year":"2004","unstructured":"Sputtek A, Sputtek R. Cryopreservation in transfusion medicine and hematology. In: Life in the frozen state. CRC Press; 2004. p. 483\u2013504."},{"issue":"5","key":"16_CR99","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.jcyt.2019.02.013","volume":"21","author":"L Wang","year":"2019","unstructured":"Wang L, Gong W, Wang S, Neuber B, Sellner L, Schubert ML, et al. Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells. Cytotherapy. 2019;21(5):566\u201378.","journal-title":"Cytotherapy"},{"key":"16_CR100","doi-asserted-by":"publisher","first-page":"1024362","DOI":"10.3389\/fonc.2022.1024362","volume":"12","author":"K Brezinger-Dayan","year":"2022","unstructured":"Brezinger-Dayan K, Itzhaki O, Melnichenko J, Kubi A, Zeltzer L-A, Jacoby E, et al. Impact of cryopreservation on CAR T production and clinical response. Front Oncol. 2022;12:1024362.","journal-title":"Front Oncol"},{"issue":"15","key":"16_CR101","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1016\/j.vaccine.2017.02.038","volume":"35","author":"T Ford","year":"2017","unstructured":"Ford T, Wenden C, Mbekeani A, Dally L, Cox JH, Morin M, et al. Cryopreservation-related loss of antigen-specific IFN\u03b3 producing CD4+ T-cells can skew immunogenicity data in vaccine trials: lessons from a malaria vaccine trial substudy. Vaccine. 2017;35(15):1898\u2013906.","journal-title":"Vaccine"},{"issue":"10","key":"16_CR102","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.exphem.2008.04.010","volume":"36","author":"A Barber","year":"2008","unstructured":"Barber A, Zhang T, Megli CJ, Wu J, Meehan KR, Sentman CL. Chimeric NKG2D receptor\u2013expressing T cells as an immunotherapy for multiple myeloma. Exp Hematol. 2008;36(10):1318\u201328.","journal-title":"Exp Hematol"},{"issue":"2","key":"16_CR103","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3390\/cells11020278","volume":"11","author":"JM Baust","year":"2022","unstructured":"Baust JM, Snyder KK, Van Buskirk RG, Baust JG. Assessment of the impact of post-thaw stress pathway modulation on cell recovery following cryopreservation in a hematopoietic progenitor cell model. Cells. 2022;11(2):278.","journal-title":"Cells"},{"issue":"3","key":"16_CR104","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/s41596-020-00467-0","volume":"16","author":"S Kiesgen","year":"2021","unstructured":"Kiesgen S, Messinger JC, Chintala NK, Tano Z, Adusumilli PS. Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity. Nat Protoc. 2021;16(3):1331\u201342.","journal-title":"Nat Protoc"},{"key":"16_CR105","series-title":"Advances in experimental medicine and biology","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/978-3-031-30040-0_11","volume-title":"Potency assays for advanced stem cell therapy medicinal products","author":"JS Burns","year":"2023","unstructured":"Burns JS. The evolving landscape of potency assays. In: Burns JS, editor. Potency assays for advanced stem cell therapy medicinal products, Advances in experimental medicine and biology, vol. 1420. Cham: Springer International Publishing; 2023. p. 165\u201389. Available from: https:\/\/link.springer.com\/10.1007\/978-3-031-30040-0_11."}],"container-title":["Advances in Experimental Medicine and Biology","Cell Therapy Manufacturing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-97297-3_16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:06:24Z","timestamp":1784207184000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-97297-3_16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783031972966","9783031972973"],"references-count":105,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-97297-3_16","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"25 October 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}